Video
Dr. Hafron highlights the most significant prostate cancer treatment advances in 2022
Author(s):
Video Player is loading.
In this interview, Jason M. Hafron, MD, recaps the biggest advances in the prostate cancer treatment paradigm in 2022. Hafron is a partner at the Michigan Institute of Urology, PC; an associate professor of Urology at the William Beaumont School of Medicine, Oakland University; and the director of Robotic Surgery at Beaumont Hospital Royal Oak in Michigan.
Related Videos
Strategies to bridge gender disparities in AAS and citations in the oncology literature
Stacy Loeb, MD, MSc, PhD (Hon), discusses the nuances of prostate cancer screening
Selecting Between Receptor Pathway Inhibitors for mHSPC
The Use of Ultra-Low PSA in Specific Patient Profiles
Fred Saad, MD, FRCS, discusses clinical impact of darolutamide approval in mCSPC
Ryan Hankins, MD, on rectal spacer utilization and erectile dysfunction
Adam Weiner, MD, on therapeutic decision-making in metastatic prostate cancer
Fred Saad, MD, FRCS, reacts to FDA approval of darolutamide in mCSPC
Using Ultrasensitive PSA Assays in Routine Practice
Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point
Related Content
